Arena to Evaluate Atugen s Antisense Technology | GenomeWeb

NEW YORK, Sept 10 – Atugen, a Berlin-based functional genomics company, said Monday that Arena Pharmaceuticals had agreed to evaluate its G-protein coupled receptor technology.

Under the terms of the deal, Atugen’s US-based subsidiary will receive central nervous system gene targets from Arena for evaluation using its GeneBlocs gene expression technologies. The company will then try to determine gene function in vivo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.